Overview
- The special commission presented its roughly 40‑page final report with 20 measures and left a window for additional submissions until December 9 to guide the incoming Congress.
- Investigators concluded the contamination occurred during manufacturing at Laboratorio Ramallo and was distributed by HLB Pharma, with multiresistant bacteria such as Klebsiella pneumoniae and Ralstonia pickettii linked to at least 124 deaths across several provinces.
- The report faults the lack of real‑time production monitoring and deficient traceability, citing the judge’s testimony that regulators depended on post‑hoc records and that authorities initially did not know where many ampoules had been sent.
- Lawmakers criticize ANMAT’s performance, note missing inspection records flagged by the court, and urge legal changes including putting ANMAT on a statutory basis, mandatory digital lot logging, national traceability for critical injectables, stronger audits, and enforceable SISA reporting.
- The judicial case in La Plata lists 14 people processed, several in custody, including HLB owner Ariel García Furfaro, as families who took part in the hearings press for accountability and decry the absences of Health Minister Mario Lugones and the ANMAT chief.